Focus: Cancer Center Featured Story 2

• share
• favorite_border

Peter Kanetsky, Ph.D., M.P.H., chair of the Cancer Epidemiology Department at Moffitt Cancer Center, and colleagues from the International TEsticular CAncer Consortium (TECAC), launched a large analysis of five major testicular cancer studies to investigate genetic risk factors linked to TGCT. Their results, which uncovered eight new genetic markers associated with TGCT, were published in the June 12 issue of Nature Genetics.

• share
• favorite_border

In a study published today in Cancer Cell, Moffitt Cancer Center researchers report that a newly discovered epigenetic mechanism can lead to the development of castration-resistant prostate cancer. They identified a novel drug that targets this epigenetic mechanism and may be able to combat the deadly form of the disease.

• share
• favorite_border

University of Colorado Cancer Center study pinpoints promising link in the chain of hedgehog signaling that, when broken, could reduce the metastatic potential of breast cancer.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Convergent R.N.R. Ltd. (CRnR) today announced a collaboration to further develop new radiation technology aimed at reducing side effects of standard radiation including unwanted radiation to healthy tissue.

• share
• favorite_border

The latest HPV vaccine could prevent most HPV infections — and millions of cancers — worldwide, according to an article by Cosette Wheeler, PhD, and her collaborators. The article describing the HPV vaccine and strategies to overcome issues with its use was published online by the American Society of Clinical Oncology.

• share
• favorite_border

The latest in childhood cancer statistics in New Jersey show significant declines in mortality rates for white, black and Hispanic children from 1979 to 2013. A Rutgers Cancer Institute of New Jersey expert says this improvement in survival can be attributed to treatment advances and participation in clinical trials.

• share
• favorite_border

While the risk of developing testicular cancer is low, every man should understand some basic facts about this disease. Rutgers Cancer Institute of New Jersey experts share more about the disease, which is the most common malignancy among men ages 15 to 35.

• share
• favorite_border

An analysis of breast cancer data revealed that many small breast cancers have an excellent prognosis because they are inherently slow growing, according to Yale Cancer Center experts.

• share
• favorite_border

Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic cancer, according to a study at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

• share
• favorite_border

In updated findings from the KEYNOTE-059 trial of pembrolizumab in advanced gastric or gastroesophageal junction (GEJ) cancer, the PD-1 inhibitor maintained signs of its clinical benefit in this patient population.

• share
• favorite_border

Walking is probably the simplest, easiest and the most inexpensive way to remain fit. Experts link a bevy of health benefits with regular walking.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered into an agreement to collaborate on research for a unique randomized clinical trial comparing the outcomes and side-effects of intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of oropharyngeal cancer of the head and neck.

• share
• favorite_border

Day-long endurance event starting at the U.S. Military Academy at West Point, NY, focused on cancer immunotherapy research

• share
• favorite_border

The University of Kansas Cancer Center and Children’s Mercy Twitter #NoTobaccoChat focused on changing the way healthcare providers treat tobacco dependence.

• share
• favorite_border

Dr. Philip McCarthy of Roswell Park Cancer Institute presents updated findings on CALGB/ECOG 100104 study of lenalidomide maintenance therapy for multiple myeloma, adjusting data to account for crossover effect.

• share
• favorite_border

Dr. Kunle Odunsi of Roswell Park Cancer Institute presented an update about an ongoing clinical trial involving T-cell engineering to treat advanced ovarian cancer at the ASCO Annual Meeting in Chicago.

• share
• favorite_border

Roswell Park and OmniSeq report that a custom algorithm they developed based on a 54-gene signature accurately predicted response to anti-PD-L1 treatment in 90% of the cases they analyzed.

• share
• favorite_border

The authors of a phase II clinical study report that combination therapy with brentuximab vedotin and gemcitabine in patients is “highly active" regimen for patients with Hodgkin lymphoma.

• share
• favorite_border

For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute-funded SWOG clinical trials program has added 3.34 million years of life for cancer patients in the United States because of successful therapies that were proved through its trials.That is the conclusion of an analysis, led by a faculty member at Fred Hutchinson Cancer Research Center, of outcomes data from 193 randomized Phase III clinical trials tested by SWOG.

• share
• favorite_border

The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center report at the 2017 annual meeting of the American Society of Clinical Oncology.

• share
• favorite_border

A recent study by Yale Cancer Center researchers revealed a 41% response to the antibody drug, enfortumab vedotin, by metastatic urothelial (mUC) tumors in a phase I clinical trial

• share
• favorite_border

In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study being presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study will also be published in a corresponding issue of JAMA Oncology.

• share
• favorite_border

Worldwide phase II clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 show the promise of the second-generation drug dasatinib against pediatric CML. Of 113 pediatric patients studied, 75 percent of patients who had previously failed or did not tolerate imatinib saw progression-free survival 48 months after starting treatment with dasatinib.

• share
• favorite_border

Study presented at ASCO 2017 shows that only 9 percent of 259 evaluated AML patients received all seven of the NCCN-recommended genetic tests.

• share
• favorite_border

A combination regimen of two immunotherapies and another of two targeted therapies each significantly shrank metastatic brain tumors in at least 50 percent of patients in separate multi-center clinical trials presented today at the 2017 ASCO Annual Meeting by principal investigators from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Updated results of a clinical trial that launched in 2007 were presented today by Ethan Basch, MD, of Memorial Sloan Kettering Cancer Center (MSK) and UNC Lineberger Comprehensive Cancer Center, at the annual meeting of the American Society of Clinical Oncology. Data showed that systematic symptom monitoring during outpatient chemotherapy using web-based patient-reported outcomes (PROs) improved overall survival.

• share
• favorite_border

The first phase III trial of a PARP inhibitor used to treat breast cancer reported promising data at the annual meeting of the American Society of Clinical Oncology (ASCO). Mark Robson, MD, Clinic Director of the Clinical Genetics Service and medical oncologist at Memorial Sloan Kettering Cancer Center (MSK), led the multicenter, international trial. He presented the study results in the plenary session of the annual meeting on June 4.

• share
• favorite_border

Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented today at the annual meeting of the American Society of Clinical Oncology in Chicago. David Hyman, MD, Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK) and global principal investigator of the NAVIGATE trial testing larotrectinib, shared the landmark data from three multisite clinical trials in a press conference at the meeting.

• share
• favorite_border

Findings from an early study evaluating a sophisticated new genomic-sequencing approach that analyzes cell-free DNA (cfDNA) in the blood of people with advanced cancer will help inform development of a future assay that could potentially detect cancer in its earliest stages, according to research presented today by a Memorial Sloan Kettering Cancer Center (MSK) investigator at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

• share
• favorite_border

A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused by a mutation of the RAS gene found in many cancers. The pre-clinical study combined therapies targeting the inhibitors polyADP ribose polymerase (PARP) and mitogen-activated protein kinase (MEK). The findings were published this week in Science Translational Medicine.

• share
• favorite_border

Immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as a preoperative treatment shows promise in early stage TNBC.

• share
• favorite_border

The National Cancer Institute (NCI) has awarded four Dana-Farber Cancer Institute researchers with Outstanding Investigator Awards (OIA) for ongoing progressive research within their respective areas of study.

• share
• favorite_border

The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects. The findings will be presented by Dr. Seth Pollack, a physician-scientist at Fred Hutchinson Cancer Research Center, June 5 in a poster at the American Society of Clinical Oncology annual meeting in Chicago.

• share
• favorite_border

The NCCN Policy Summit: Ensuring Patient Access and Safety in Cancer Care takes place on Thursday, June 15, 2017, from 9:30 am – 3:00 pm at the National Press Club in Washington, DC.

• share
• favorite_border

• share
• favorite_border

A genetic test that helps doctors determine how best to treat breast cancer—and whether chemotherapy is likely to help—is significantly more likely to be administered to white women than blacks or Hispanics, a Yale study has found.

• share
• favorite_border

Cancer Immunotherapy Month in June to feature educational and awareness programming for patients, caregivers, and the public

• share
• favorite_border

By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, according to a Phase 2 clinical trial led by an investigator at Fred Hutchinson Cancer Research Center.

• share
• favorite_border

Dana-Farber Cancer Institute has named Lesley Solomon to the newly-created position of senior vice president for innovation and chief innovation officer. Solomon has been serving as executive director of the Brigham Innovation Hub at Brigham and Women’s Hospital and director of strategy and innovation in the Brigham Research Institute.

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

The American Cancer Society estimates more than 95,000 Americans will be diagnosed with colon cancer this year. Dr. Charles Fuchs at Yale Cancer Center discusses way to prevent the disease.

• share
• favorite_border

The vaccine for HPV is proving to have significant population-level effects in Connecticut, a new Yale School of Public Health study finds.

• share
• favorite_border

Moffitt researchers have developed a test called the radiosensitivity index that determines how sensitive a patient’s tumor is to radiation therapy. The radiosensitivity index is based on the expression of different genes in a patient’s tumor and has been validated in 9 different patient groups across different tumor types.

• share
• favorite_border

New Collaboration Will Grant CancerLinQ Subscribers Streamlined Access to the NCCN Compendium®

• share
• favorite_border

Ludwig Cancer Research released today the full scope of Ludwig’s participation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6.

• share
• favorite_border

Combo of T-cell therapy, newly FDA-approved drug and another immunotherapeutic agent kept cancer at bay for three out of four patients with metastatic Merkel cell carcinoma. The findings will be presented June 5 at the annual meeting of the American Society of Clinical Oncology.

• share
• favorite_border

As many as 53 percent of cancer patients’ Emergency Department visits that do not require admission could be avoided with better symptom management and greater availability of outpatient care tailored to their needs, according to a new study from Fred Hutchinson Cancer Research Center. This study will be presented at the 2017 American Society for Clinical Oncology meeting on June 5, 2017. It is Abstract #6505 (link here: http://abstracts.asco.org/199/AbstView_199_193735.html).

• share
• favorite_border

These studies were funded through a collaboration with AstraZeneca to evaluate the effectiveness of osimertinib in EGFRm+ non-small cell lung cancer